Endostatin Genetically Engineered Placental Mesenchymal Stromal Cells Carrying Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Combined Chemo- and Antiangiogenic Therapy

Combination therapies constitute a powerful tool for cancer treatment. By combining drugs with different mechanisms of action, the limitations of each individual agent can be overcome, while increasing therapeutic benefit. Here, we propose employing tumor-migrating decidua-derived mesenchymal stroma...

Full description

Bibliographic Details
Main Authors: Paz de la Torre, Juan L. Paris, Miguel Fernández-de la Torre, María Vallet-Regí, Ana I. Flores
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/13/2/244
_version_ 1797411900573614080
author Paz de la Torre
Juan L. Paris
Miguel Fernández-de la Torre
María Vallet-Regí
Ana I. Flores
author_facet Paz de la Torre
Juan L. Paris
Miguel Fernández-de la Torre
María Vallet-Regí
Ana I. Flores
author_sort Paz de la Torre
collection DOAJ
description Combination therapies constitute a powerful tool for cancer treatment. By combining drugs with different mechanisms of action, the limitations of each individual agent can be overcome, while increasing therapeutic benefit. Here, we propose employing tumor-migrating decidua-derived mesenchymal stromal cells as therapeutic agents combining antiangiogenic therapy and chemotherapy. First, a plasmid encoding the antiangiogenic protein endostatin was transfected into these cells by nucleofection, confirming its expression by ELISA and its biological effect in an ex ovo chick embryo model. Second, doxorubicin-loaded mesoporous silica nanoparticles were introduced into the cells, which would act as vehicles for the drug being released. The effect of the drug was evaluated in a coculture in vitro model with mammary cancer cells. Third, the combination of endostatin transfection and doxorubicin-nanoparticle loading was carried out with the decidua mesenchymal stromal cells. This final cell platform was shown to retain its tumor-migration capacity in vitro, and the combined in vitro therapeutic efficacy was confirmed through a 3D spheroid coculture model using both cancer and endothelial cells. The results presented here show great potential for the development of combination therapies based on genetically-engineered cells that can simultaneously act as cellular vehicles for drug-loaded nanoparticles.
first_indexed 2024-03-09T04:53:02Z
format Article
id doaj.art-637892d5ebda4fd380110b52da63810c
institution Directory Open Access Journal
issn 1999-4923
language English
last_indexed 2024-03-09T04:53:02Z
publishDate 2021-02-01
publisher MDPI AG
record_format Article
series Pharmaceutics
spelling doaj.art-637892d5ebda4fd380110b52da63810c2023-12-03T13:09:08ZengMDPI AGPharmaceutics1999-49232021-02-0113224410.3390/pharmaceutics13020244Endostatin Genetically Engineered Placental Mesenchymal Stromal Cells Carrying Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Combined Chemo- and Antiangiogenic TherapyPaz de la Torre0Juan L. Paris1Miguel Fernández-de la Torre2María Vallet-Regí3Ana I. Flores4Grupo de Medicina Regenerativa, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avda. Cordoba s/n 28041, 28041 Madrid, SpainDepartamento de Química en Ciencias Farmacéuticas (Unidad Docente de Química Inorgánica y Bioinorgánica), Facultad de Farmacia, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28040 Madrid, SpainGrupo de Enfermedades Raras, Mitocondriales y Neuromusculares, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avda. Cordoba s/n 28041, 28041 Madrid, SpainDepartamento de Química en Ciencias Farmacéuticas (Unidad Docente de Química Inorgánica y Bioinorgánica), Facultad de Farmacia, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28040 Madrid, SpainGrupo de Medicina Regenerativa, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avda. Cordoba s/n 28041, 28041 Madrid, SpainCombination therapies constitute a powerful tool for cancer treatment. By combining drugs with different mechanisms of action, the limitations of each individual agent can be overcome, while increasing therapeutic benefit. Here, we propose employing tumor-migrating decidua-derived mesenchymal stromal cells as therapeutic agents combining antiangiogenic therapy and chemotherapy. First, a plasmid encoding the antiangiogenic protein endostatin was transfected into these cells by nucleofection, confirming its expression by ELISA and its biological effect in an ex ovo chick embryo model. Second, doxorubicin-loaded mesoporous silica nanoparticles were introduced into the cells, which would act as vehicles for the drug being released. The effect of the drug was evaluated in a coculture in vitro model with mammary cancer cells. Third, the combination of endostatin transfection and doxorubicin-nanoparticle loading was carried out with the decidua mesenchymal stromal cells. This final cell platform was shown to retain its tumor-migration capacity in vitro, and the combined in vitro therapeutic efficacy was confirmed through a 3D spheroid coculture model using both cancer and endothelial cells. The results presented here show great potential for the development of combination therapies based on genetically-engineered cells that can simultaneously act as cellular vehicles for drug-loaded nanoparticles.https://www.mdpi.com/1999-4923/13/2/244mesenchymal stromal cellsmesoporous silica nanoparticlescombination therapyantiangiogenic therapy
spellingShingle Paz de la Torre
Juan L. Paris
Miguel Fernández-de la Torre
María Vallet-Regí
Ana I. Flores
Endostatin Genetically Engineered Placental Mesenchymal Stromal Cells Carrying Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Combined Chemo- and Antiangiogenic Therapy
Pharmaceutics
mesenchymal stromal cells
mesoporous silica nanoparticles
combination therapy
antiangiogenic therapy
title Endostatin Genetically Engineered Placental Mesenchymal Stromal Cells Carrying Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Combined Chemo- and Antiangiogenic Therapy
title_full Endostatin Genetically Engineered Placental Mesenchymal Stromal Cells Carrying Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Combined Chemo- and Antiangiogenic Therapy
title_fullStr Endostatin Genetically Engineered Placental Mesenchymal Stromal Cells Carrying Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Combined Chemo- and Antiangiogenic Therapy
title_full_unstemmed Endostatin Genetically Engineered Placental Mesenchymal Stromal Cells Carrying Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Combined Chemo- and Antiangiogenic Therapy
title_short Endostatin Genetically Engineered Placental Mesenchymal Stromal Cells Carrying Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Combined Chemo- and Antiangiogenic Therapy
title_sort endostatin genetically engineered placental mesenchymal stromal cells carrying doxorubicin loaded mesoporous silica nanoparticles for combined chemo and antiangiogenic therapy
topic mesenchymal stromal cells
mesoporous silica nanoparticles
combination therapy
antiangiogenic therapy
url https://www.mdpi.com/1999-4923/13/2/244
work_keys_str_mv AT pazdelatorre endostatingeneticallyengineeredplacentalmesenchymalstromalcellscarryingdoxorubicinloadedmesoporoussilicananoparticlesforcombinedchemoandantiangiogenictherapy
AT juanlparis endostatingeneticallyengineeredplacentalmesenchymalstromalcellscarryingdoxorubicinloadedmesoporoussilicananoparticlesforcombinedchemoandantiangiogenictherapy
AT miguelfernandezdelatorre endostatingeneticallyengineeredplacentalmesenchymalstromalcellscarryingdoxorubicinloadedmesoporoussilicananoparticlesforcombinedchemoandantiangiogenictherapy
AT mariavalletregi endostatingeneticallyengineeredplacentalmesenchymalstromalcellscarryingdoxorubicinloadedmesoporoussilicananoparticlesforcombinedchemoandantiangiogenictherapy
AT anaiflores endostatingeneticallyengineeredplacentalmesenchymalstromalcellscarryingdoxorubicinloadedmesoporoussilicananoparticlesforcombinedchemoandantiangiogenictherapy